Stock Track | Eli Lilly Soars 5.86% in Pre-Market on Strong Q4 Earnings Beat and Upbeat 2026 Guidance

Stock Track

Feb 04

Eli Lilly's stock surged 5.86% in pre-market trading following the release of its fourth-quarter 2025 financial results, which significantly exceeded analyst expectations.

The pharmaceutical giant reported Q4 adjusted earnings per share of $7.54, surpassing the IBES estimate of $6.67. Revenue for the quarter reached $19,292 million, also beating the consensus estimate of $17,959 million and representing a 43% year-over-year increase. The company's weight-loss drug Zepbound contributed $4,261 million in revenue during the period.

Furthermore, Eli Lilly provided optimistic guidance for 2026, forecasting adjusted EPS in the range of $33.50 to $35, which exceeds the FactSet estimate of $33.04. The company also projected full-year revenue between $80,000 million and $83,000 million, signaling continued strong growth expectations.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1167368777"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1167368777\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1167368777?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-04 19:48","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1167368777","market":"sg","top_or_hot":-1,"title":"Stock Track | Eli Lilly Soars 5.86% in Pre-Market on Strong Q4 Earnings Beat and Upbeat 2026 Guidance","media":"Stock Track","content":"<p>Eli Lilly's stock surged 5.86% in pre-market trading following the release of its fourth-quarter 2025 financial results, which significantly exceeded analyst expectations.</p><p>The pharmaceutical giant reported Q4 adjusted earnings per share of $7.54, surpassing the IBES estimate of $6.67. Revenue for the quarter reached $19,292 million, also beating the consensus estimate of $17,959 million and representing a 43% year-over-year increase. The company's weight-loss drug Zepbound contributed $4,261 million in revenue during the period.</p><p>Furthermore, Eli Lilly provided optimistic guidance for 2026, forecasting adjusted EPS in the range of $33.50 to $35, which exceeds the FactSet estimate of $33.04. The company also projected full-year revenue between $80,000 million and $83,000 million, signaling continued strong growth expectations.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Eli Lilly Soars 5.86% in Pre-Market on Strong Q4 Earnings Beat and Upbeat 2026 Guidance</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Eli Lilly Soars 5.86% in Pre-Market on Strong Q4 Earnings Beat and Upbeat 2026 Guidance\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-02-04 19:48</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Eli Lilly's stock surged 5.86% in pre-market trading following the release of its fourth-quarter 2025 financial results, which significantly exceeded analyst expectations.</p><p>The pharmaceutical giant reported Q4 adjusted earnings per share of $7.54, surpassing the IBES estimate of $6.67. Revenue for the quarter reached $19,292 million, also beating the consensus estimate of $17,959 million and representing a 43% year-over-year increase. The company's weight-loss drug Zepbound contributed $4,261 million in revenue during the period.</p><p>Furthermore, Eli Lilly provided optimistic guidance for 2026, forecasting adjusted EPS in the range of $33.50 to $35, which exceeds the FactSet estimate of $33.04. The company also projected full-year revenue between $80,000 million and $83,000 million, signaling continued strong growth expectations.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LLY","symbol_name":"礼来","start_time":0,"source_url":"","article_id":"1167368777","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1167368777","pubTimestamp":1770205734,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Eli Lilly's stock surged 5.86% in pre-market trading following the release of its fourth-quarter 2025 financial results, which significantly exceeded analyst expectations.The pharmaceutical giant...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LLY":"礼来"},"translate_title":"个股追踪|礼来公司盘前飙升5.86%，第四季度盈利强劲，2026年指引乐观","themeId":"bcb73b9a2718796b6bdfcc143da1014d","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LLY":1},"content_text":"Eli Lilly's stock surged 5.86% in pre-market trading following the release of its fourth-quarter 2025 financial results, which significantly exceeded analyst expectations.The pharmaceutical giant reported Q4 adjusted earnings per share of $7.54, surpassing the IBES estimate of $6.67. Revenue for the quarter reached $19,292 million, also beating the consensus estimate of $17,959 million and representing a 43% year-over-year increase. The company's weight-loss drug Zepbound contributed $4,261 million in revenue during the period.Furthermore, Eli Lilly provided optimistic guidance for 2026, forecasting adjusted EPS in the range of $33.50 to $35, which exceeds the FactSet estimate of $33.04. The company also projected full-year revenue between $80,000 million and $83,000 million, signaling continued strong growth expectations.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}